8-year-sustained response in a patient with isolated del(5q) myelodysplastic syndrome undergoing continuous treatment with lenalidomide: a case report

详细信息    查看全文

• 作者：OA Dr. Martin Farkas
• 关键词：Myelodysplastic syndrome ; MDS with deletion of chromosome 5q ; del(5q) MDS ; Lenalidomide ; Long ; term transfusion independence
• 刊名：memo - Magazine of European Medical Oncology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：9
• 期：1
• 页码：48-51
• 全文大小：448 KB
• 参考文献：1.Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC Press; 2008.
  2.Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385–95.CrossRef PubMed
  3.Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90(9):1168–78.PubMed
  4.Kelaidi C, Park S, Brechignac S, et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008;32(7):1049–53.CrossRef PubMed
  5.Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12(1):5–10.CrossRef PubMed
  6.Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev. 2009;23(Suppl. 1):S15–9.CrossRef PubMed
  7.Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26(6):1286–92.CrossRef PubMed
  8.Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia. 2011;25(1):110–20.CrossRef PubMed
  9.Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–76.CrossRef PubMed
  10.List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.CrossRef PubMed
  11.Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.CrossRef PubMed PubMedCentral
  12.Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104(27):11406–11.CrossRef PubMed PubMedCentral
  13.Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523(7559):183–8.CrossRef PubMed
  14.List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28(5):1033–40.CrossRef PubMed PubMedCentral
  15.Giagounidis A, Fenaux P, Mufti GJ, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol. 2008;87(5):345–52.CrossRef PubMed PubMedCentral
  16.Gohring G, Giagounidis A, Busche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89(4):365–74.CrossRef PubMed
  17.Giagounidis AA, Kulasekararaj A, Germing U, et al. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia. 2012;26(4):855–8.CrossRef PubMed
  18.Pisani F, Orlandi G, Merola R. Long-term response in a patient with del(5q) myelodysplastic syndrome who discontinued lenalidomide and obtained a good response and tolerance to rechallenge. Case Rep. Oncol. 2014;7(1):277–84.PubMed PubMedCentral
  19.Kurtin SE, List AF. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clin Lymphoma Myeloma. 2009;9(3):E10–3.CrossRef PubMed
  20.Giagounidis AA, Haase S, Heinsch M, Gohring G, Schlegelberger B, Aul C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol. 2007;86(2):133–7.CrossRef PubMed PubMedCentral
  21.Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025–37.CrossRef PubMed
  22.Ades L, Le BF, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica. 2012;97(2):213–8.CrossRef PubMed PubMedCentral
  23.Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 2013;27(5):1072–9.CrossRef PubMed PubMedCentral
  24.Sanchez-Garcia J, Del CC, Lorenzo I, et al. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. Br J Haematol. 2014;166(2):189–201.CrossRef PubMed
  25.Mallo M, Del RM, Ibanez M, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol. 2013;162(1):74–86.CrossRef PubMed
  26.Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2008;26(36):5943–9.CrossRef PubMed PubMedCentral
  27.Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol. 2011;29(15):1971–9.CrossRef PubMed
  28.Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51(12):1086–92.CrossRef PubMed
  29.Belickova M, Cermak J, Dostalova MM, et al. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q). Clin Lymphoma Myeloma Leuk. 2012;12(5):375–83.CrossRef PubMed
  30.Sardnal V, Rouquette A, Kaltenbach S, et al. A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia. 2013;27(7):1610–3.CrossRef PubMed
  
• 作者单位：OA Dr. Martin Farkas (1)
  
  1. Division for Hemato-Oncology, 1st Department for Internal Medicine, Landesklinikum Wiener Neustadt, Corvinusring 3–5, 2700, Wiener Neustadt, Austria
  
• 刊物主题：Oncology; Medicine/Public Health, general;
• 出版者：Springer Vienna
• ISSN：1865-5076

文摘

The advent of lenalidomide has fundamentally changed the treatment of patients with myelodysplastic syndrome (MDS) and deletion of the long arm of chromosome 5 (del(5q)), inducing high rates of red blood cell transfusion independence and cytogenetic response. We report a case of an 84-year-old patient with International Prognostic Scoring System (IPSS)-defined low-risk MDS with isolated del(5q), who has received continuous lenalidomide treatment for the past 8 years and whose treatment is ongoing. Grade 3 or 4 neutropenia and thrombocytopenia, which occurred in approximately 60 % of the patients during the first weeks of treatment, did not occur in our patient. Also, there were no thromboembolic events or a progression to acute myeloid leukemia. This case highlights the role of lenalidomide in modifying the course of low-risk del(5q) MDS in long-term responders by inducing a durable hematologic response and thereby contributing to control iron overload and improving long-term outcomes in selected patients.